Abstract
This narrative review examines barriers to Danish patients' timely access to new treatments for treatment-resistant depression, focusing on controversies around esketamine. Delays arise from regulatory complexity, economic constraints and scientific debate over novel psychotropics. The review advocates evidence-based, faster implementation pathways for new treatments to alleviate the overall individual and societal burden from severe depression in Denmark.
| Originalsprog | Engelsk |
|---|---|
| Artikelnummer | A02260078 |
| Tidsskrift | Danish Medical Journal |
| Vol/bind | 73 |
| Udgave nummer | 9 |
| Antal sider | 9 |
| ISSN | 2245-1919 |
| DOI | |
| Status | Udgivet - 2026 |
Citationsformater
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS